Krystal Biotech Inc (KRYS)vsMerck & Company Inc (MRK)
KRYS
Krystal Biotech Inc
$350.88
+5.10%
HEALTHCARE · Cap: $9.88B
MRK
Merck & Company Inc
$150.91
+0.94%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 15013% more annual revenue ($66.57B vs $440.48M). KRYS leads profitability with a 54.8% profit margin vs 4.8%. KRYS trades at a lower P/E of 41.9x. KRYS earns a higher WallStSmart Score of 65/100 (C+).
KRYS
Buy65
out of 100
Grade: C+
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KRYS.
Margin of Safety
-77.2%
Fair Value
$83.04
Current Price
$150.91
$67.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 55 of every $100 in revenue as profit
Strong operational efficiency at 49.0%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 24.1% year-over-year
Earnings expanding 38.8% YoY
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.9x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : KRYS
The strongest argument for KRYS centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 54.8% and operating margin at 49.0%. Revenue growth of 24.1% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : KRYS
The primary concerns for KRYS are P/E Ratio. A P/E of 41.9x leaves little room for execution misses.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
KRYS profiles as a growth stock while MRK is a value play — different risk/reward profiles.
KRYS carries more volatility with a beta of 0.54 — expect wider price swings.
KRYS is growing revenue faster at 24.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
KRYS scores higher overall (65/100 vs 36/100), backed by strong 54.8% margins and 24.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Krystal Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?